🧬 HER2 Cancer Research

HER2 (human epidermal growth factor receptor 2) is a protein that plays a critical role in the growth and development of certain cancer cells. When HER2 is overexpressed—meaning cancer cells produce abnormally high levels of this protein—it can fuel rapid cell growth and division. This occurs in approximately 15-20% of breast cancers and a significant portion of gastric cancers, making HER2 status one of the most important biomarkers in modern oncology. Understanding HER2 expression has revolutionized cancer diagnosis and treatment, allowing doctors to identify which patients may benefit from targeted therapies specifically designed to block HER2 signaling.

Research into HER2 continues to advance at a rapid pace, with scientists working to develop new diagnostic tools, targeted medications, and combination therapies that can more effectively treat HER2-positive cancers while minimizing side effects. Recent studies have expanded our knowledge about HER2 mutations, resistance mechanisms, and how to better predict treatment response. For patients and caregivers navigating a HER2-positive cancer diagnosis, staying informed about the latest research developments is essential for understanding treatment options and emerging clinical trials.

On this page, you'll find the latest peer-reviewed research articles on HER2 as a cancer biomarker and diagnostic tool. These studies represent the cutting edge of scientific investigation into how HER2 testing and targeted approaches are improving cancer outcomes.